Atsena Therapeutics
Jen Franks, Ph.D., is a seasoned scientist with extensive experience in research and development within the biotechnology sector. Currently serving as Scientist II at Atsena Therapeutics since September 2024, Jen previously held positions as Senior Scientist at Creyon Bio and as a Scientist at Adrenas Therapeutics, where key contributions included designing and presenting in vitro cell culture studies focused on genetic restoration using CRISPR-Cas approaches. Jen's academic background is rooted in a Ph.D. in Pharmacology from the University of North Carolina at Chapel Hill, complemented by prior roles such as Graduate Research Scientist and Laboratory Manager at notable institutions like the Icahn School of Medicine at Mount Sinai and Dana-Farber Cancer Institute. Jen's leadership skills were demonstrated as Vice President of Internal Affairs for the Graduate Business & Consulting Club at UNC-Chapel Hill, overseeing internal communications and event management.
This person is not in any teams
Atsena Therapeutics
Atsena Therapeutics is a clinical-stage gene therapy company focused on bringing the life-changing power of genetic medicine to reverse or prevent blindness. They have an ongoing Phase I/II clinical trial evaluating a potential therapy for one of the most common causes of blindness in children. Their additional pipeline of leading preclinical assets is powered by an adeno-associated virus (AAV) technology platform tailored to overcome significant hurdles presented by inherited retinal disease.